Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK045368-05
Application #
2016546
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1992-09-30
Project End
1997-09-29
Budget Start
1996-09-30
Budget End
1997-09-29
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
University of Oklahoma Health Sciences Center
Department
Urology
Type
Schools of Medicine
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117

  Publications

Birckbichler, P J; Bonner, R B; Hurst, R E et al. (2000) Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer 89:412-23
Hemstreet 3rd, G P; Rao, J; Hurst, R E et al. (1999) Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prev 23:163-71
Waliszewski, P; Waliszewska, M; Gordon, N et al. (1999) Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells. Mol Cell Endocrinol 148:55-65
Rao, J Y; Bonner, R B; Hurst, R E et al. (1997) Quantitative changes in cytoskeletal and nuclear actins during cellular transformation. Int J Cancer 70:423-9
Bonner, R B; Liebert, M; Hurst, R E et al. (1996) Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Cancer Epidemiol Biomarkers Prev 5:971-8
Hemstreet 3rd, G P; Rao, J; Hurst, R E et al. (1996) G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. J Cell Biochem Suppl 25:197-204